Quest diagnostics drug test sensitivity1/28/2024 The new Quest Diagnostics Drug Testing Index™ (DTI) report is based on more than 10.6 million deidentified urine, hair and oral-fluid drug test results reported between January and December 2022, aimed at providing insight into behavior seen in workers across the combined U.S. "As employers express concern for employee health, wellness and safety, they may want to consider these data as a warning sign, particularly as a growing body of science demonstrates the risks of marijuana to mental and physical health." "Year-over-year and five-year data point to continuously higher workforce drug positivity overall, by industry, and across multiple drug categories," said Suhash Harwani, PhD, Senior Director of Science for Employer Solutions at Quest Diagnostics. The increase in amphetamines positivity is also notable, given the addictive potential and health risks associated with this class of drugs." "This historic rise seems to correspond with sharp increases in positivity for marijuana in both pre-employment and post-accident drug tests, suggesting that changing societal attitudes about marijuana may be impacting workplace behaviors and putting colleagues at risk. workforce positivity rate continued to be at a historically elevated level in 2022, even as much of the nation's workforce returned to the office post-pandemic," said Keith Ward, General Manager and Vice President for Employer Solutions at Quest Diagnostics. "Our 2022 Quest Diagnostics analysis shows that the overall U.S. Over the past five years, the workforce positivity rate climbed in most industry sectors, led by Accommodation and Food Services increasing 42.9% (4.9% in 2018 versus 7.0% in 2022), Retail Trade increasing 42.6% (5.4% in 2018 versus 7.7% in 2022), and Finance and Insurance increasing 38.5% (2.6% in 2018 versus 3.6% in 2022). The rising overall drug positivity rate for general workforce urine testing was observed widely across U.S. While the company's amphetamines data does not differentiate between prescribed medications and illicit drug use, the increase correlates with other data suggesting that the use of amphetamines, prescribed or illicit, has grown in recent years in the U.S. workforce increased 10.3% (4.3% positivity in 2022 versus 3.9% positivity in 2021) and amphetamines positivity increased 15.4% (1.5% positivity in 2022 versus 1.3% positivity in 2021). Positivity for marijuana in the general U.S. workforce, amphetamines positivity also contributed to the increase. While marijuana was the main driver of workforce positivity increases in the general U.S. The 20 positivity rates were the highest since 2001, up more than 30% from an all-time low in 2010-2012. workforce urine drug positivity for all drugs persisted at 4.6% – the highest level in two decades. It is imperative employers take the proper steps to create and maintain a policy that addresses cannabis use, build a safety-focused culture and educate the workforce to keep all workers safe on and off the job." "The Quest data provide compelling evidence that increased use of cannabis products by employees can contribute to greater risk for injuries in the workplace. State legalization of the drug creates new challenges for employers," said Katie Mueller, a senior program manager at the National Safety Council focusing on cannabis safety. "Intoxicating cannabis products, including marijuana, can have a major impact on safety at work and have been proven to slow reaction time, impact memory and impair skills essential to driving. Since then, 19 additional states and the District of Columbia have legalized the recreational use of marijuana and 38 states (plus the District of Columbia) have legalized medical use, although either kind of use remains illegal under federal law. In 2012, Colorado and Washington became the first states to legalize marijuana for recreational use. These increases in post-accident marijuana positivity correspond with legalization of marijuana in certain states. From 2002 to 2009, post-accident marijuana workforce positivity declined. In that 10-year time frame, post-accident marijuana positivity increased 204.2%. The new peak follows a steady increase in post-accident marijuana positivity every year from 2012 to 2022. workforce was 7.3%, an increase of 9% compared to 6.7% in 2021. In 2022, post-accident marijuana positivity of urine drug tests in the general U.S. Post-Accident Workforce Drug Positivity for Marijuana Reached 25-Year High in 2022, Quest Diagnostics Drug Testing Index Analysis Finds
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |